Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ASPH | Q12797 | 1/20 | 0.35 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356938 | 0.91 | MTOR (0.39) | TEAD1LSSKCNH2HRH3IDO1 | |
| SCHEMBL17356978 | 0.86 | MLYCD (0.41) | TEAD1HRH3 | |
| SCHEMBL17356975 | 0.85 | HRH3 (0.39) | HRH3NAMPTBCHEACHEBACE1 | |
| SCHEMBL14703466 | 0.84 | KCNH2 (0.45) | TEAD1LSSKCNH2HRH3NAMPT | |
| SCHEMBL14703438 | 0.84 | KCNH2 (0.42) | TEAD1LSSKCNH2HRH3NAMPT | |
| SCHEMBL14703143 | 0.83 | KDM4E (0.46) | TEAD1LSSKCNH2HRH3NAMPT | |
| SCHEMBL17356979 | 0.82 | P2RX7 (0.44) | IDO1P2RX7 | |
| SCHEMBL17356951 | 0.81 | NPC1 (0.42) | NAMPT | |
| SCHEMBL17777459 | 0.81 | CHKA (0.44) | TEAD1LSSKCNH2HRH3NAMPT | |
| SCHEMBL17777599 | 0.79 | TEAD1 (0.43) | TEAD1LSSKCNH2HRH3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252996-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KP) | 2018-04-19 | — | — | US | disclosed |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KP) | 2018-04-19 | — | — | US | disclosed |
| US-9884821-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884821-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | IMMUNOMET THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | IMMUNOMET THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | PRKG1, PRKAG1, PRKG2 | TEAD1 2421/4885LSS 4845/4885KCNH2 997/4885 |
| US-10252996-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | PRKG1, PRKAG1, PRKG2 | TEAD1 2421/4885LSS 4845/4885KCNH2 997/4885 |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PRKG1, PRKAG1, PRKG2 | TEAD1 2421/4885LSS 4845/4885KCNH2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.